Irreversible proteasome inhibition with carfilzomib as first line therapy in patients with newly diagnosed multiple myeloma: early in vivo cardiovascular effects
Articolo
Data di Pubblicazione:
2018
Citazione:
Irreversible proteasome inhibition with carfilzomib as first line therapy in patients with newly diagnosed multiple myeloma: early in vivo cardiovascular effects / Gavazzoni, M; Lombardi, C; Vizzardi, E; Gorga, E; Sciatti, E; Rossi, Laura; Belotti, A; Rossi, G; Metra, M; Raddino, R. - In: EUROPEAN JOURNAL OF PHARMACOLOGY. - ISSN 0014-2999. - (2018).
Tipologia CRIS:
1.1 Articolo in rivista
Elenco autori:
Gavazzoni, M; Lombardi, C; Vizzardi, E; Gorga, E; Sciatti, E; Rossi, Laura; Belotti, A; Rossi, G; Metra, M; Raddino, R
Link alla scheda completa:
Pubblicato in: